Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic

Excerpt from the Press Release:

SPRINGFIELD, Mo. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Fight Colorectal Cancer (Fight CRC), the nation’s leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back to routine colorectal cancer screening.

The award, called “Back to Screening Award for Research Advocacy Excellence,” will honor key contributions made by Fight CRC research advocates, as well as Principal Investigators participating in Guardant Health’s ECLIPSE trial, a clinical study evaluating the use of a blood test to screen for colorectal cancer. Selected recipients of the award will be honored at Fight CRC’s “Path to a Cure” event in December 2021. Notably, this year’s event will convene a group of research and advocacy experts who will be tasked with mapping out a path leading to a cure for colorectal cancer. The framework will be shared with the National Cancer Institute (NCI) and National Institutes of Health (NIH) to request action to help achieve this goal.

Click the button below to read the entire Press Release:

Continue Reading The Press Release